# A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

> **NCT02968173** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 50 (actual)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **DRUG:** Palivizumab

## Key facts

- **NCT ID:** NCT02968173
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-09
- **Primary completion:** 2017-07-13
- **Final completion:** 2017-07-13
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02968173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02968173, "A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02968173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*